Potentiation of actinomycin D or adriamycin antitumor activity with DNA
- PMID: 1260747
Potentiation of actinomycin D or adriamycin antitumor activity with DNA
Abstract
Several antitumor agents known to bind DNA were complexed with this macromolecule and tested for activity against experimental animal tumor systems. Combination studies with these agents and DNA were carried out at the same time. Actinomycin D activity against the P388 lymphocytic leukemia in BALB/c X DBA/2 F1 mice was significantly potentiated by calf thymus DNA, both when complexed and when injected in combination. The DNA could be given as much as 4 hr before or after the antibiotic and still give potentiation. Synergism was also obtained when the DNA was autoclaved prior to complexing and/or injecting. Similarly, adriamycin activity against the L1210 lymphoid leukemia in DBA/2 mice was significantly potentiated by autoclaved herring sperm DNA, both as a complex and when injected in combination. When above-optimal levels of adriamycin were complexed with autoclaved herring sperm DNA and injected into BALB/c mice inoculated with the Madison 109 alveogenic carcinoma, the early lethality was delayed and antitumor activity was sometimes observed. Herring sperm DNA injected alone also had antitumor activity against the Madison 109 tumor. Similarly, activity was obtained against this tumor system with calf thymus DNA and actinomycin D when injected alone. In addition, DNA, in combination and when complexed with actinomycin, prevented the toxicity observed with BALB/c mice, inoculated with the Madison 109 tumor, were given injections of an above-optimal dose of this antibiotic.
Similar articles
-
N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.Cancer Res. 1975 May;35(5):1365-8. Cancer Res. 1975. PMID: 1054622
-
DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.Res Commun Chem Pathol Pharmacol. 1975 Jan;10(1):51-64. Res Commun Chem Pathol Pharmacol. 1975. PMID: 1124321
-
Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.Cancer Res. 1982 Feb;42(2):440-4. Cancer Res. 1982. PMID: 7055799
-
Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.Cancer Res. 1983 Jun;43(6):2880-3. Cancer Res. 1983. PMID: 6573953
-
Role of host defense merchanisms in the antitumor activity of adriamycin and daunomycin in mice.J Natl Cancer Inst. 1979 Jul;63(1):61-6. J Natl Cancer Inst. 1979. PMID: 286835 No abstract available.
Cited by
-
Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects.Nucleic Acids Res. 2023 May 8;51(8):3540-3555. doi: 10.1093/nar/gkad156. Nucleic Acids Res. 2023. PMID: 36919604 Free PMC article.
-
Cytostatic efficacy of DNA-complexes of adriamycin, daunomycin and actinomycin D. I. Comparative studies in Novikoff hepatoma, human mammary carcinoma cells and human leukemic leukocytes.Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1977 May 20;89(1):75-86. doi: 10.1007/BF02571692. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1977. PMID: 195410
-
In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor.Cancer Chemother Pharmacol. 1979;2(1):43-7. doi: 10.1007/BF00253104. Cancer Chemother Pharmacol. 1979. PMID: 498419
-
Cystostatic efficacy of DNA-complexes of adriamycin, daunomycin, and actinomycin D. II. Comparative in vivo studies in an Ehrlich-ascites tumor.Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1977 Dec 15;90(3):307-12. doi: 10.1007/BF00284304. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1977. PMID: 146332
-
Isolation and structure determination of a new antibacterial peptide pentaminomycin C from Streptomyces cacaoi subsp. cacaoi.J Antibiot (Tokyo). 2020 Apr;73(4):224-229. doi: 10.1038/s41429-019-0272-y. Epub 2020 Jan 10. J Antibiot (Tokyo). 2020. PMID: 31919422